BioXcel Therapeutics, Inc.: cashflow_financing
| Value | {"amount": 50871000, "concept": "us-gaap:NetCashProvidedByUsedInFinancingActivities", "currency": "USD"} |
|---|---|
| Period | 2025-01-01 – 2025-09-30 |
| Status | current |
| Entity | BioXcel Therapeutics, Inc. |
Provenance
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
Retrieved: 2026-08-19T17:36:10.925466+02:00
Raw response sha256:
Also addressable by official identifiers:
Cite as: FACTANKER, https://factanker.com/fact/57032e03-5ce4-48fc-823b-89fa60816053
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
0001104659-25-109880Retrieved: 2026-08-19T17:36:10.925466+02:00
Raw response sha256:
f7bde1a401b286c74a2fd824ee1df541…Also addressable by official identifiers:
https://factanker.com/fact/sec/cik-0001720893/cashflow-financing/2025-09-30 (CIK, metric, reporting date)Cite as: FACTANKER, https://factanker.com/fact/57032e03-5ce4-48fc-823b-89fa60816053
History
- no predecessors — first report